



**Internship**  
**Investment Analyst**  
**Start TBD, period 5–6 months**

---

**Aescap, investing in public biotech/life sciences companies, is looking for a Bio-medical/Business student for an internship as Investment Analyst**

---

#### **Our Funds**

Our two investment funds, Aescap Life Sciences and Aescap Genetics, invest in publicly traded biotech / life sciences companies. They both invest in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics and medical devices.

Our Aescap Life Sciences fund has a focused portfolio, investing in a variety of around 20 – 25 companies that exploit numerous different medical technologies. In order to reduce the risks of investing in this sector, the fund diversifies its portfolio over many disease areas, different phases of company development and geographical areas. The fund invests mainly in Europe and the US.

In January 2022, six years after the launch of Aescap Life Sciences, our second fund called Aescap Genetics was launched. The Genetics fund invests exclusively in the fast-growing market of RNA, gene and cell therapy medicines.

Investment decisions are based on fundamental analysis of the upside potential, technological risk factors and relative undervaluation of a company (risk adjusted DCF).

#### **Investment Analyst Intern**

In the role of Investment Analyst intern at Aescap you will be involved in supporting the team's activities of looking for the most promising biopharmaceutical companies in US and Europe. You will help evaluate these companies by determining their intrinsic value by looking at both qualitative as well as quantitative aspects of the companies and their targeted markets. You will be involved in research regarding clinical trials, treatment guidelines, scientific literature and overall biotechnology market trends.

During your internship you will gain an extensive knowledge of the healthcare market and all its dynamics. The start of the internship is flexible.

## Your Profile

- Master's degree or above with a major in Pharmacy, Biochemistry or any other related disciplines and a Business/Finance training.
- A specialization in the field of gene/cell therapy would be a plus.
- Excellent analytical and communication skills with strong desire to learn and succeed.
- Entrepreneurial drive with strong interpersonal and networking skills.
- Excellent verbal and written communication skills in English.

## Scope of Responsibilities

- Perform quantitative and qualitative due diligence involving reviewing clinical trials and treatment guidelines.
- Conduct technology reviews/assessments on topics of interest for the fund.
- Support the team in monitoring the portfolio companies and other companies in our working universe.
- Gather intelligence on strategic topics in the broader biotech/healthcare market.
- Present results of your work to the team in an effective manner.
- Be part of and contribute to the discussions within the team regarding companies in our portfolio or in our deal flow.
- Handle any ad hoc tasks as assigned

## The Team

The [team of Aescap](#) is led by Patrick Krol. Patrick has been a private investor in public biotech companies for over 30 years. Since 2005 he is active at Aescap as a professional investor in biotech/life sciences companies. He acted as a board director of 10 biotech and medical diagnostics companies.

You will be working closely with the Analyst team: Paolo Del Bufalo, who joined Aescap in 2018 and studied both biochemistry and Science Based Business at Leiden University in The Netherlands and Etienne Daher, who joined Aescap in 2021 and studied Pharmacy and Corporate Strategy/Management at ESSEC Business School in France.

Aescap is also supported by four experienced portfolio advisors and a network of 20+ medical/industry scouts

To apply, please send your motivation letter and CV to [service@aescap.com](mailto:service@aescap.com)

Feel free to reach out to us for any questions you might have.